Skip to main content
HLB SCIENCE Inc. logo

HLB SCIENCE Inc. — Investor Relations & Filings

Ticker · 343090 ISIN · KR7343090007 KO Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2021-06-15 Capital/Financing Update
Country KR South Korea
Listing KO 343090

About HLB SCIENCE Inc.

https://hlbscience.com/eng/index.php

HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the decision to issue convertible bonds (전환사채권 발행결정). It details the terms of the issuance, including interest rates, conversion prices, put/call options, and the use of proceeds. This falls under the category of capital and financing updates.
2021-06-15 Korean
기업설명회(IR)개최결과
Report Publication Announcement Classification · 100% confidence The document is a short, structured announcement detailing the results of an Investor Relations (IR) meeting held by Dandi Bio. It provides the date, location, attendees, and a summary of the topics covered (company status, outlook, Q&A). It does not contain the full presentation slides or a transcript, but rather serves as a formal notification that the event occurred and where the materials can be found. Given its nature as a regulatory notification of an event outcome, it fits best under the RNS (Regulatory Filings) category as a general regulatory announcement.
2021-05-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special relations (insider transactions/disposals). This falls under the 'Major Shareholding Notification' category.
2021-05-06 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) presentation. It specifies the date, time, location (online), target audience, and purpose of the event. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a standard corporate disclosure notice.
2021-05-03 Korean
증권발행결과(자율공시)(제2회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement regarding the issuance of convertible bonds (CB) by Dandi Bioscience. It details the issuance method, amount, and payment date. This falls under the category of capital and financing updates, specifically related to the issuance of new securities or debt instruments.
2021-04-22 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a 'Major Report/Exchange Reporting Requirement' (주요사항보고서/거래소신고의무사항) regarding the issuance of convertible bonds (전환사채권 발행결정). It details specific amendments to call option periods and other terms of the bond issuance. Since this is a regulatory filing detailing changes to a corporate financing event (capital structure change) and does not fit into the specific categories of Annual Reports, Earnings Releases, or simple announcements, it is classified as a Capital/Financing Update.
2021-04-21 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.